1’. opioid craving ↓↓ 2’. No withdrawal symptoms 3’. or absent opioid misuse ↓ 4. No further dose adjustments needed 4.. Maintenance phase (Months 3-12) (Slide 37) a. Optimal dose reached b. Work on relapse prevention to support abstinence H. Evidence buprenorphine maintenance works (Slide 38) 1. Buprenorphine maintenance (at better than placebo and naltrexone re: ≥16mg/day) a. Treatment retention b. positive urines ↓Opioid 2. Buprenorphine versus methadone (Slide 39) a. Both improve outcomes, but methadone with greater patient retention b. Buprenorphine carries benefit of office-based Rx and safer during induction VII. Conclusions (Slide 40) A. Opioid Use Disorder (OUD) is common and dangerous. B. Buprenorphine is a partial agonist at the receptor with a favorable safety profile. μ-opioid C. Buprenorphine is an effective treatment for the treatment of OUD. D. Buprenorphine in combination with naloxone reduces misuse and diversion. References:
1’. ↓↓ opioid craving 2’. No withdrawal symptoms 3’. ↓ or absent opioid misuse 4. No further dose adjustments needed 4.. Maintenance phase (Months 3-12) (Slide 37) a. Optimal dose reached b. Work on relapse prevention to support abstinence H. Evidence buprenorphine maintenance works (Slide 38) 1. Buprenorphine maintenance (at ≥16mg/day) better than placebo and naltrexone re: a. Treatment retention b. ↓Opioid positive urines 2. Buprenorphine versus methadone (Slide 39) a. Both improve outcomes, but methadone with greater patient retention b. Buprenorphine carries benefit of office-based Rx and safer during induction VII. Conclusions (Slide 40) A. Opioid Use Disorder (OUD) is common and dangerous. B. Buprenorphine is a partial agonist at the μ-opioid receptor with a favorable safety profile. C. Buprenorphine is an effective treatment for the treatment of OUD. D. Buprenorphine in combination with naloxone reduces misuse and diversion. References:
Buprenorphine-2016.docx